Tani Masaji, Kawai Manabu, Terasawa Hiroshi, Ina Shinomi, Hirono Seiko, Uchiyama Kazuhisa, Yamaue Hiroki
Second Department of Surgery, Wakayama Medical University, School of Medicine, Japan.
J Surg Oncol. 2006 May 1;93(6):485-90. doi: 10.1002/jso.20440.
In our study, we investigated whether postoperative chemotherapy improved survival in patients with invasive ductal carcinoma of the pancreas. Between 1987 and 2004, 111 patients underwent pancreatic resection against invasive ductal carcinoma of the pancreas in Wakayama Medical University Hospital. Median survival time (MST) was 19.4 months, 8.6 months, and 7.2 months, in JPS Stage III (UICC Stage IIA and IIB), JPS Stage IVa (UICC Stage IIA and IIB), and JPS Stage IVb (UICC Stage IV), respectively (P < 0.01). The MST of the chemotherapy group was 12 months, and the MST of the non-chemotherapy group was 8.4 months (P < 0.05). Moreover, in JPS Stage IV (UICC Stage IIA, IIB, III, and IV) highly advanced pancreatic cancer, the MST of the chemotherapy group was 10.9 months, and the MST of the group without chemotherapy was 6.6 months (P < 0.01). Since pancreatic cancer is characterized by an aggressive tumor with a high recurrent rate, postoperative chemotherapy is effective for an improvement of survival.
在我们的研究中，我们调查了术后化疗是否能改善胰腺浸润性导管癌患者的生存率。1987年至2004年间，和歌山县医科大学医院有111例患者因胰腺浸润性导管癌接受了胰腺切除术。在日本胰腺学会（JPS）III期（国际抗癌联盟（UICC）IIA期和IIB期）、JPS IVa期（UICC IIA期和IIB期）和JPS IVb期（UICC IV期）患者中，中位生存时间（MST）分别为19.4个月、8.6个月和7.2个月（P<0.01）。化疗组的MST为12个月，非化疗组的MST为8.4个月（P<0.05）。此外，在JPS IV期（UICC IIA期、IIB期、III期和IV期）的高度进展性胰腺癌中，化疗组的MST为10.9个月，未化疗组的MST为6.6个月（P<0.01）。由于胰腺癌具有肿瘤侵袭性强、复发率高的特点，术后化疗对提高生存率有效。
